PARG-IN-4 free base

PARG-IN-4) is an orally active and cell-permeable PARG inhibitor.

For research use only. Not for human or veterinary use.

Target Poly(ADP-ribose) Glycohydrolase (PARG) Apoptosis

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

PARG-IN-4 structure

CAS No.: 2988890-20-4

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 580.00	BP-02061-50mg	In stock	Get quote
100 mg	USD 928.00	BP-02061-100mg	In stock	Get quote
250 mg	USD 1,378.00	BP-02061-250mg	In stock	Get quote
500 mg	Inquire	BP-02061-500mg	In stock	Inquire
1 g	Inquire	BP-02061-1g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

PARG-IN-4 (Formula (A)) is an orally active and cell-permeable PARG inhibitor. PARG-IN-4 effectively inhibits tumor growth in mouse models. PARG-IN-4 can be used in cancer research.

Biological activity

In Vitro PARG-IN-4 (Formula (A)) affects the cell viability of SNU601 and RMUGS cells with EC50 of 11 nM and 4.2 nM, respectively; and exhibits antiproliferative activity against ovarian and breast cancer cells. In Vivo PARG-IN-4 (Formula (A)) (100 mg/kg; po; QD; 45 d) induces tumor regression in a patient-derived HBCx-34 xenograft mouse model.

Identifiers

SMILES: CC1(CC1)NS(=O)(C2=CC(N3C[C@@H](N[C@H](C3)C)C)=C(C=NN4C5=NN=C(C(F)F)S5)C4=C2)=O
InChIKey: AQOUTSJIZZVANZ-RYUDHWBXSA-N

Specifications

MW (average): 497.5850
Formula: C₂₀H₂₅F₂N₇O₂S₂
CAS No.: 2988890-20-4
Physical state: Solid
Color: Light yellow to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month

Solubility

Soluble in DMSO : 20 mg/mL

Documents

References

[1]. Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1.

Same target

Search Poly(ADP-ribose) Glycohydrolase (PARG)

Same research area

Search Cancer